van Langevelde A, Bakker C N, Boer H, Ilmer T A, Journée-de Korver J A, Kaspersen F M, Noach E L, Oosterhuis J A, Pauwels E K
Eur J Nucl Med. 1986;12(2):96-104. doi: 10.1007/BF00364737.
The uptake and distribution of several 4-(substituted amino)-iodoquinolines, 131I-labelled, and of 67Ga-citrate were investigated in Syrian golden hamsters with Greene melanomas. Because of its uptake in the melanoma (tumour/eye ratio 8.9), 4-(dimethylamino-ethylamino)-7-iodoquinoline (NM113) was selected for further investigations as a possible radiopharmaceutical for ocular scintigraphy when labelled with 123I. High uptake of NM113 turned out to be incidental and could not be favourably influenced by several pharmacological pretreatments. Affinity for melanin, as shown in in vitro experiments, unfavourably influences NM113 tumour-to-eye ratios. In comparison with 67Ga-citrate, the latter, with a high tumour-to-eye ratio (44.8 after 24 h) is more promising in patient studies in which NM113 123I was not.
在患有格林黑色素瘤的叙利亚金仓鼠中，研究了几种131I标记的4-（取代氨基）-碘喹啉以及柠檬酸镓的摄取和分布情况。由于4-（二甲基氨基-乙氨基）-7-碘喹啉（NM113）在黑色素瘤中的摄取（肿瘤/眼睛比率为8.9），当用123I标记时，它被选作进一步研究的对象，作为一种可能用于眼部闪烁显像的放射性药物。结果表明，NM113的高摄取是偶然的，并且不能通过几种药理学预处理得到有利影响。体外实验显示，对黑色素的亲和力不利地影响了NM113的肿瘤与眼睛比率。与柠檬酸镓相比，后者具有较高的肿瘤与眼睛比率（24小时后为44.8），在患者研究中比NM113 123I更有前景。
